Mesalazine
- PDF / 169,750 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 20 Downloads / 135 Views
1
S
Skin rash with elevated laboratory findings: case report In a retrospective cohort study conducted between April 2000 and September 2018, one patient [age and sex not stated] was described, who developed skin rash and exhibited high concentration of macro-creatine phosphokinase along with increased pancreatic and liver enzymes during treatment with mesalazine for intestinal Behcet’s disease (BD). The patient, who had intestinal BD, was scheduled to receive remission induction and maintenance therapy with an extended-release oral mesalazine [Pentasa; 5-aminosalicylic acid] initially for 8 weeks, followed by endoscopic evaluation to check treatment efficacy [dosage not stated]. However, prior to the endoscopic evaluation, the treatment was discontinued due to skin rash and high concentration of macro-creatine phosphokinase along with increased pancreatic and liver enzymes, which were considered to be possibly related to mesalazine. Following discontinuation of mesalazine, all the reactions resolved without any sequelae. Author comment: "Seven patients (17%) developed an [adverse event] that was assessed as possibly related to [mesalazine] . . . One patient (2.4%) developed a skin rash, elevation of liver and pancreas enzymes, and a high macrocreatine phosphokinase concentration." Kinoshita H, et al. Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behcet’s disease. Journal of Gastroenterology and Hepatology 34: 1929-1939, No. 11, Nov 2019. Available 803443310 from: URL: http://doi.org/10.1111/jgh.14690 - Japan
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
